Study of molecular markers of coagulation and fibrinolysis in patients with maligant diseases

Zhou He-bing,Liu Fu-qiang,Yan Shu-xu,Zhai Yan-ling,Zhang Juan,Wang Li,Li Li-hong
DOI: https://doi.org/10.3969/j.issn.1004-8685.2008.02.044
2008-01-01
Abstract:Objective:The antigens as molecular markers of coagulation and fibrinolysis systems were measured in patients with malignant tumors in order to investigate their changes among the patients with acute leukemia(AL),malignant lymphoma(ML) and solid tumors.Methods:By enzyme-linked immunosorben assay(ELISA),4 plasma molecular markers of the coagulation and fibrinolysis systems were measured in 30 healthy volunteers and 47 cases of malignant tumors that included 27 patients with AL,in which 21 newly-diagnosed AL,6 relapsed cases,10 patients with ML and 10 patients with solid tumor.Their blood samples were taken from their veins at fasting in the morning,with anticoagulant of 3.8% sodium citrate.These molecular markers of coagulation and fibrinolytic system were as followings: tissue factor(TF),Thrombin——antithrombin complexes(TAT),tissue-type plasminogen activator(t-PA),plasminogen activator inhibitor-1(PAI-1).Results:1.The levels of TF in 47 cases of malignant tumors were all significantly higher than that in control group,TF level in ML group was significantly higher than that in AL group;2.TAT levels in the group of AL,ML group and solid tumor group were all significantly higher than that in control group respectively;3.The levels of t-PA in 3 groups of malignant tumors were all significantly higher than that in control group,the solid tumor group was significantly higher than AL group.4.The PAI-1 levels in AL group or in solid tumor group were significantly higher than that in control group.Conclusion:In patients with acute leukemia,lymphoma and solid tumor,there are the similar coagulation and fibrinolysis aberrancy that are predisposed to blood coagulation and inhibition of fibrinolysis.
What problem does this paper attempt to address?